Skip to content

Protagenic Therapeutics, Inc.\new: cash and cash equivalents

Protagenic Therapeutics, Inc.\new cash and cash equivalents: $671.1 thousand at 2020-12-31, down 16.0% on the year. 11 values since 2013 from SEC filings.

All Protagenic Therapeutics, Inc.\new financial histories

At a glance

Protagenic Therapeutics, Inc.\new reported cash and cash equivalents of $671.1 thousand at 2020-12-31, down 16.0% from $798.6 thousand a year earlier. From 2013 to 2020 it fell at a compound 0.9% a year, from $717.0 thousand to $671.1 thousand. Across the last five reported years it ranged from $362.5 thousand (2018-12-31) to $3.10 million (2016-12-31). That was 76.3% of total assets ($879.2 thousand) at the same date.

Computed from the values in the table below, in USD; each links to the filing it came from.

What this measure means

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Exact concept: us-gaap:CashAndCashEquivalentsAtCarryingValue. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2013-06-30 to 2020-12-31. The SEC response was captured on 2026-09-20.

This selected history ends more than two years before capture. Do not treat its final value as a current balance or current annual result. More recent filings may use another accounting tag; inspect the filings before drawing conclusions about the company.

Selected filing history

Cash and cash equivalents in original reported units, latest-filed observation per period
Period startPeriod endValueUnitFiledSource filing
-2020-12-31671,091USD2021-03-2510-K · 0001493152-21-006756 SEC
-2019-12-31798,623USD2021-03-2510-K · 0001493152-21-006756 SEC
-2018-12-31362,486USD2020-04-2910-K · 0001493152-20-007286 SEC
-2017-12-31399,687USD2019-03-2910-K · 0001493152-19-004288 SEC
-2016-12-313,100,398USD2019-03-2910-K · 0001493152-19-004288 SEC
-2015-12-313,343USD2018-04-0210-K · 0001493152-18-004567 SEC
-2015-06-3062,000USD2015-09-2510-K · 0001144204-15-056587 SEC
-2014-12-3122,733USD2017-05-0810-K/A · 0001437749-17-008187 SEC
-2014-06-30101,000USD2015-09-2510-K · 0001144204-15-056587 SEC
-2013-07-11717,000USD2015-09-2510-K · 0001144204-15-056587 SEC
-2013-06-30717,000USD2014-10-1410-K · 0001144204-14-060987 SEC

Related Protagenic Therapeutics, Inc.\new histories

All 36 Protagenic Therapeutics, Inc.\new histories

Inspect the source

Entity
Protagenic Therapeutics, Inc.\new / CIK 0001022899
Captured
SEC response SHA-256
65b45c5addd26cd3e105dbeb1582537b1352dc73c447a8d926c77d81587fc033

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

The MCP server is free and MIT-licensed: npx -y canli-mcp. If these records help your research, a star on GitHub helps other researchers find them.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001022899.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))